CG018 inhibitors are a class of compounds specifically designed to inhibit the activity of the CG018 protein, a molecule involved in certain cellular processes related to signaling or regulation, though its precise biological role may not be fully characterized in all contexts. Proteins like CG018 are often part of larger cellular networks, interacting with various other molecules to influence processes such as transcription, cellular metabolism, or structural organization. By inhibiting CG018, these compounds prevent the protein from performing its normal functions, which could affect its interactions with other proteins or its role in cellular pathways. This inhibition allows for the study of how CG018 impacts cellular regulation and how its activity influences broader biological processes.
The mechanism by which CG018 inhibitors work typically involves binding to the protein in a way that blocks its active sites or disrupts its ability to interact with other molecules within the cell. This can lead to altered cellular signaling or metabolic regulation, depending on the specific functions of CG018 in a given cell type. Researchers use CG018 inhibitors as tools to probe the protein's role in cellular dynamics, investigating how the inhibition of this protein affects pathways such as gene expression, protein modification, or cellular structure. Through the use of these inhibitors, scientists can better understand the importance of CG018 in maintaining normal cellular function and how its activity contributes to the regulation of various biochemical pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
A NEDD8-activating enzyme inhibitor, potentially affecting N4BP2L1 by disrupting NEDD8-related ubiquitination processes. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
A ubiquitin-activating enzyme E1 inhibitor, which could indirectly affect N4BP2L1 by inhibiting ubiquitination. | ||||||
NSC697923 | 343351-67-7 | sc-391107 sc-391107A | 1 mg 5 mg | $15.00 $52.00 | 3 | |
A UBE2N inhibitor, potentially influencing N4BP2L1 activity by affecting ubiquitin-conjugating enzymes. | ||||||
Histone Lysine Methyltransferase Inhibitor Inhibitor | 935693-62-2 (free base) | sc-202651 | 5 mg | $151.00 | 4 | |
A histone methyltransferase inhibitor, could indirectly affect N4BP2L1 through epigenetic regulation. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor, which might influence N4BP2L1 activity by affecting protein degradation. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Another proteasome inhibitor, potentially impacting N4BP2L1 through the inhibition of protein degradation pathways. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
An autophagy inhibitor, which could indirectly affect N4BP2L1 by impacting lysosomal degradation pathways. | ||||||
PHA 665752 | 477575-56-7 | sc-203186 sc-203186A sc-203186B sc-203186C | 2 mg 10 mg 50 mg 200 mg | $143.00 $281.00 $714.00 $1510.00 | 24 | |
An inhibitor of autophagy, potentially affecting N4BP2L1 by inhibiting early stages of autophagosome formation. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
An autophagy inhibitor, which might influence N4BP2L1 activity by inhibiting the fusion between autophagosomes and lysosomes. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor, which could indirectly affect N4BP2L1 by modulating autophagy and protein synthesis pathways. | ||||||